• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

     Inpatient Research Program

    Program Description:

    The Treatment Research Unit (TRU) was established in 1989 as a joint venture between the Maryland Department of Health (MDH) and the University of Maryland at Baltimore (UMB), with the dual mission of providing state of the art clinical care to patients with treatment-resistant schizophrenia while conducting research on novel treatments for this difficult illness.  Consisting of one 24-bed unit, the TRU is operated and staffed by Spring Grove Hospital.  The research mission is under the guidance of the Maryland Psychiatric Research Center (MPRC), a division of the Department of Psychiatry at UMB.  The research program is currently managed and directed by Deanna L. Kelly, PharmD, BCPP, Professor of Psychiatry as part of the MPRC Treatment Research Program.  The clinical unit and staff are supervised by Charles Richardson, MD, Staff Psychiatrist with Spring Grove Hospital.  At the TRU, clinical and research staff work collaboratively to provide an enhanced therapeutic experience for patients, providing expert, evidence-based, pharmaco-therapy, and state of the art psychosocial and rehabilitation-focused therapies.

    Research Program:

    Since its inception, the TRU has been a recruitment site for numerous medication trials that have targeted treatment-resistant psychosis, negative symptoms, and cognitive deficits in patients with Schizophrenia and Schizoaffective Disorder.  Under Dr. Kelly’s direction, the research program has also addressed substance use and medical co-morbidities associated with schizophrenia and its treatment.  Research participation is strictly voluntary and generally follows a period of open treatment optimization.  Patients are educated about research opportunities and they must demonstrate an understanding of the protocol and its risks before they can consent to participate.

    Psychosocial Treatments:

    While every effort is made to control symptoms through optimal pharmaco-therapy, the majority of our patients are still burdened with significant functional, financial, and social deficits.  Given that reality, the TRU’s psychosocial interventions are designed to foster personal recovery and rehabilitation.  Our goal is to help our patients understand and manage their illnesses in order to refocus on living their lives.   Therapeutic interventions include occupational and recreation therapies, motivational interviewing, cognitive-behavioral therapy, psycho-education, and family support.  We strive to help our patients re-establish family relationships and personal interests, and to transition to the community.  Disposition planning is client-centered, and is perhaps our most important activity.

    Family Involvement:

    The maintenance and repair of family relations is hugely important to our patients’ well-being and recovery.  Family support is also critical to accomplishing our research mission.  Thus, family involvement is encouraged at every stage of treatment.  Families are contacted at the time of referral and are encouraged to visit prior to admission and throughout the hospitalization.  Families are educated about research opportunities and a Family Education and Support Group is held each month

    Referral Process:

    The TRU accepts patient referrals from throughout the State of Maryland.  Admission Criteria include:
    • Males and Females between 18 and 65.
    • Diagnoses of Schizophrenia and Schizoaffective Disorder
    • Persistent symptoms that prevent safe community functioning

    Exclusion Criteria include:

    • Mental Retardation and Neurologic Disorders independent of Schizophrenia
    • Unstable medical conditions
    • Legal status that would prevent research participation such as Guardianship of Person or Court Ordered treatment
    On referral, the TRU’s recruiter will contact the referring agency and interview the referred patient to determine eligibility and interest.  When possible, patients and their families are encouraged to visit the TRU prior to accepting admission, to meet clinical staff and tour the unit.
    To obtain further information or to make a referral, please contact:
    Mandy Porta, LCSW-C
    For specific information on clinical trial information, please contact:
    Stephanie M. Feldman LCSW-C

    Contact Us 

    Clinical Staff:

    Charles Richardson, MD
    Psychiatrist and Unit Director
    Gopal Vyas, DO
    Elizabeth Gale, LCSW-C
    Social Worker
    Kelly Dutcher, LCSW-C
    Social Worker
    Michelle Kuptzin, OTR
    Occupational Therapist
    Anne Padgett, CTRS
    Activity Therapist
    Mandy Porta, LCSW-C
    Unit Recruiter
    Heather Adams, PsyD
    Claribel Okafor, RN
    Head Nurse
    Research Staff:
    Deanna L. Kelly, PharmD, BCPP
    Professor of Psychiatry
    Director and Chief
    Treatment Research Program
    Susan Basham
    Karen Horn
    Administrative Assistant
    Stephanie M. Feldman, MSW, LCSW-C
    Director of Research Operations
    Dale Warfel, RN
    Research Nurse
    Ann Marie Kearns, BA
    Specialist, Research Compliance
    Kelli Sullivan, BS
    Research Counselor
    Amber Earl, MS
    Clinical Research Assistant
    Fang Liu, MS
    Heidi Wehring, PharmD, BCPP
    Assistant Professor
    Kimberly Warren, PhD
    Assistant Professor